TY - JOUR
T1 - Anti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis
AU - on behalf of the Childhood Myositis Heterogeneity Collaborative Study Group
AU - Pinal-Fernandez, Iago
AU - Pak, Katherine
AU - Gil-Vila, Albert
AU - Baucells, Andres
AU - Plotz, Benjamin
AU - Casal-Dominguez, Maria
AU - Derfoul, Assia
AU - Martinez-Carretero, Maria Angeles
AU - Selva-O'Callaghan, Albert
AU - Sabbagh, Sara
AU - Casciola-Rosen, Livia
AU - Albayda, Jemima
AU - Paik, Julie
AU - Tiniakou, Eleni
AU - Danoff, Sonye K.
AU - Lloyd, Thomas E.
AU - Miller, Frederick W.
AU - Rider, Lisa G.
AU - Christopher-Stine, Lisa
AU - Mammen, Andrew L.
AU - Schmeling, Heinrike
AU - Arabshahi, Bita
AU - Balboni, Imelda
AU - Ballinger, Susan
AU - Barillas-Arias, Lilliana
AU - Becker, Mara
AU - Bingham, Catherine April
AU - Bohnsack, John F.
AU - Carrasco, Ruy
AU - Cartwright, Victoria
AU - Cawkwell, Gail D.
AU - Curiel, Rodolfo
AU - Dare, Jason
AU - DeGuzman, Marietta M.
AU - Eade, Kaleo
AU - Ebernardt, Barbara Anne
AU - Edelheit, Barbara S.
AU - El-Hallak, Moussa
AU - Finkel, Terri H.
AU - George, Stephen W.
AU - Goldmuntz, Ellen A.
AU - Gottlieb, Beth
AU - Graham, Brent
AU - Hannan, William
AU - Henrickson, Michael
AU - Higgins, Gloria C.
AU - Hobday, Patricia
AU - Hoftman, Alice
AU - Hong, Sandy
AU - Huber, Adam
N1 - Publisher Copyright:
© 2021 American College of Rheumatology. This article has been contributed to by US Government employees and their work is in the public domain in the USA.
PY - 2022/2
Y1 - 2022/2
N2 - Objective: To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis. Methods: In this longitudinal cohort study, anti-cortactin autoantibody titers were assessed by enzyme-linked immunosorbent assay in 670 adult myositis patients and 343 juvenile myositis patients as well as in 202 adult healthy controls and 90 juvenile healthy controls. The prevalence of anti-cortactin autoantibodies was compared among groups. Clinical features of patients with and those without anti-cortactin autoantibodies were also compared. Results: Anti-cortactin autoantibodies were more common in adult dermatomyositis (DM) patients (15%; P = 0.005), particularly those with coexisting anti–Mi-2 autoantibodies (24%; P = 0.03) or anti–NXP-2 autoantibodies (23%; P = 0.04). In adult myositis, anti-cortactin was associated with DM skin involvement (62% of patients with anti-cortactin versus 38% of patients without anti-cortactin; P = 0.03), dysphagia (36% versus 17%; P = 0.02) and coexisting anti–Ro 52 autoantibodies (47% versus 26%; P = 0.001) or anti-NT5c1a autoantibodies (59% versus 33%; P = 0.001). Moreover, the titers of anti-cortactin antibodies were higher in patients with interstitial lung disease (0.15 versus 0.12 arbitrary units; P = 0.03). The prevalence of anti-cortactin autoantibodies was not different in juvenile myositis patients (2%) or in any juvenile myositis subgroup compared to juvenile healthy controls (4%). Nonetheless, juvenile myositis patients with these autoantibodies had a higher prevalence of “mechanic's hands” (25% versus 7%; P = 0.03), a higher number of hospitalizations (2.9 versus 1.3; P = 0.04), and lower peak creatine kinase values (368 versus 818 IU/liter; P = 0.02) than those without anti-cortactin. Conclusion: The prevalence of anti-cortactin autoantibodies is increased in adult DM patients with coexisting anti–Mi-2 or anti–NXP-2 autoantibodies. In adults, anti-cortactin autoantibodies are associated with dysphagia and interstitial lung disease.
AB - Objective: To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis. Methods: In this longitudinal cohort study, anti-cortactin autoantibody titers were assessed by enzyme-linked immunosorbent assay in 670 adult myositis patients and 343 juvenile myositis patients as well as in 202 adult healthy controls and 90 juvenile healthy controls. The prevalence of anti-cortactin autoantibodies was compared among groups. Clinical features of patients with and those without anti-cortactin autoantibodies were also compared. Results: Anti-cortactin autoantibodies were more common in adult dermatomyositis (DM) patients (15%; P = 0.005), particularly those with coexisting anti–Mi-2 autoantibodies (24%; P = 0.03) or anti–NXP-2 autoantibodies (23%; P = 0.04). In adult myositis, anti-cortactin was associated with DM skin involvement (62% of patients with anti-cortactin versus 38% of patients without anti-cortactin; P = 0.03), dysphagia (36% versus 17%; P = 0.02) and coexisting anti–Ro 52 autoantibodies (47% versus 26%; P = 0.001) or anti-NT5c1a autoantibodies (59% versus 33%; P = 0.001). Moreover, the titers of anti-cortactin antibodies were higher in patients with interstitial lung disease (0.15 versus 0.12 arbitrary units; P = 0.03). The prevalence of anti-cortactin autoantibodies was not different in juvenile myositis patients (2%) or in any juvenile myositis subgroup compared to juvenile healthy controls (4%). Nonetheless, juvenile myositis patients with these autoantibodies had a higher prevalence of “mechanic's hands” (25% versus 7%; P = 0.03), a higher number of hospitalizations (2.9 versus 1.3; P = 0.04), and lower peak creatine kinase values (368 versus 818 IU/liter; P = 0.02) than those without anti-cortactin. Conclusion: The prevalence of anti-cortactin autoantibodies is increased in adult DM patients with coexisting anti–Mi-2 or anti–NXP-2 autoantibodies. In adults, anti-cortactin autoantibodies are associated with dysphagia and interstitial lung disease.
KW - Adult
KW - Age Factors
KW - Autoantibodies/genetics
KW - Cohort Studies
KW - Cortactin/immunology
KW - Female
KW - Humans
KW - Longitudinal Studies
KW - Male
KW - Middle Aged
KW - Myositis/diagnosis
KW - Phenotype
UR - http://www.scopus.com/inward/record.url?scp=85119296457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119296457&partnerID=8YFLogxK
U2 - 10.1002/art.41931
DO - 10.1002/art.41931
M3 - Article
C2 - 34313394
AN - SCOPUS:85119296457
SN - 2326-5191
VL - 74
SP - 358
EP - 364
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 2
ER -